Another Positive Study of Ovarian Carcinoma
Authors:
J. Chovanec
Authors‘ workplace:
Oddělení Gynekologické onkologie, MOÚ Brno
Published in:
Klin Onkol 2012; 25(5): 386
Category:
Oncology Highlights
Sources
1. ÚZIS ČR. NOR ČR. Novotvary 2009 ČR. ÚZIS ČR, NOR ČR 2012. Dostupné z: http://www.uzis.cz/publikace/novotvary-2009.
2. Burger RA, Brady MF, Bookman MA et al. Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365(26): 2473–2483.
3. Perren TJ, Swart AM, Pfisterer J et al. ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365(26): 2484–2896.
4. Aghajanian C, Finkler NJ, Rutherford T et al. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). 2012 ASCO Annual Meeting Abstract No: LBA5007.
5. Pujade-Lauraine E. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). 2012 ASCO Annual Meeting Abstract No: LBA5002.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2012 Issue 5
- Metamizole vs. Tramadol in Postoperative Analgesia
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
- Possibilities of Using Metamizole in the Treatment of Acute Primary Headaches
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
Most read in this issue
- Uterine Sarcomas – a Review
- Analysis of Prognostic Factors in Osteosarcoma Adult Patients, a Single Institution Experience
- Bloodstream Infections of the Intravascular Access Devices – Case Reports and Review of the Literature
- BRAF Mutation: a Novel Approach in Targeted Melanoma Therapy